Medroxyprogesterone acetate (MAP) in high doses in the treatment of breast cancer in advanced stages
Pannuti, F.; Di Marco, A.R.; Martoni, A.; Fruet, F.; Strocchi, E.; Burroni, P.; Marraro, D.
Minerva Ginecologica 34(11): 977-979
1982
ISSN/ISBN: 0026-4784 PMID: 7155427 Document Number: 188773
Document emailed within 1 workday
Related Documents
Guarnieri, A.; Tucci, E.; D'Aniello, C.; Carli, A.; Mariani, L.; De Stefano, A.; Nardi, P. 1984: Oral route administration of medroxyprogesterone acetate (MAP) at high doses in the treatment of advanced breast cancer: clinical results Chemioterapia: International Journal of the Mediterranean Society of ChemoTherapy 3(5): 320-323Sturm, G.; Antal, E.; Schmidt Rhode, P.; Bauer, T.; Schulz K D. 1986: Medroxyprogesterone acetate and immunoreactive medroxyprogesterone acetate metabolites measured by two different selective radioimmunoassay antibodies in medroxyprogesterone acetate treated breast cancer patients Anticancer Research 6(3 Part A): 362
Nomura, Y.; Tashiro, H.; Hisamatsu, K.; Toi, M. 1988: Effects of high-dose medroxyprogesterone acetate in advanced breast cancer, with special reference to prior endocrine therapy and hormone receptors Gan to Kagaku Ryoho. Cancer and ChemoTherapy 15(3): 513-518
Lorenz, I.; Mechl, Z. 1985: Medroxyprogesterone acetate versus tamoxifen in the therapy of advanced breast cancer Neoplasma 32(1): 119-124
Møller, K.A.; Andersen, A.P. 1981: Peroral administration of medroxyprogesterone acetate (MPA) in advanced cancer of the breast. A preliminary report Acta obstetricia et gynecologica Scandinavica. Supplement 101: 47-48
Tchekmedyian, N.S.; Tait, N.; Abrams, J.; Aisner, J. 1988: High-dose megestrol acetate in the treatment of advanced breast cancer Seminars in Oncology 15(2 Suppl 1: 44-49
Sadoff, L.; Lusk, W. 1974: The effect of large doses of medroxyprogesterone acetate (MPA) on urinary estrogen levels and serum levels of cortisol T4 LH and testosterone in patients with advanced cancer Obstetrics and Gynecology 43(2): 262-267
Pannuti, F.; Pollutri, E.; Martoni, A.; Camera, P.; Lenaz, G.R. 1974: Medroxyprogesterone (map) in massive doses in oncology: effects of treatment on the ECG in a group of patients with advanced breast carcinoma Bollettino della Societa Italiana di Biologia Sperimentale 50(9): 557-561
Sasagawa, I.; Satomi, S.; Katayama, T. 1989: Remarkable pain relief in the treatment with high-dose medroxyprogesterone acetate in advanced prostatic carcinoma Gan no Rinsho. Japan Journal of Cancer Clinics 35(6): 767-771
Kihara, M.; Kontani, K.; Yamauchi, A.; Yokomise, H. 2005: Two cases of advanced breast cancer responding to oral chemoendocrine therapy with 5'-deoxy-5-fluorouridine, medroxyprogesterone acetate and cyclophosphamide (DMpC) Gan to Kagaku Ryoho. Cancer and ChemoTherapy 32(5): 683-686
McDaniel, E.B.; Pardthaisong, T. 1973: Incidence of breast nodules in women receiving multiple doses of medroxyprogesterone acetate Journal of Biosocial Science 5(1): 83-88
Telimaa, S.; Kauppila, A.; Rönnberg, L.; Suikkari, A.M.; Seppälä, M. 1989: Elevated serum levels of endometrial secretory protein PP14 in patients with advanced endometriosis. Suppression by treatment with danazol and high-dose medroxyprogesterone acetate American Journal of Obstetrics and Gynecology 161(4): 866-871
Sica, G.; Iacopino, F.; Marini, L.; Robustelli della Cuna, G. 1992: Antiproliferative effect of leuprorelin acetate, alone or combined with tamoxifen or medroxyprogesterone acetate, on human breast cancer cell lines Clinical Therapeutics 14 Suppl A: 87-96
Pannuti, F. 1977: Modern prospects in the treatment of cancer of the breast and its metastasis. Medroxyprogesterone in massive doses as an alternative to polychemotherapy Minerva Chirurgica 32(19): 1211-1220
Sonoo, H.; Senoo, T.; Nishiki, M.; Morimoto, T.; Takashima, S. 1996: Effectiveness of combination hormonal therapies in advanced or recurrent breast cancer--a randomized trial of tamoxifen (TAM), medroxyprogesterone acetate (MPA), their simultaneous combination, and an alternating sequential combination of TAM plus MPA Gan to Kagaku Ryoho. Cancer and ChemoTherapy 23(4): 447-454
Toi, M.; Taniguchi, T.; Hayashi, K.; Tominaga, T. 1995: The effect of combination treatment consisted of 5'-deoxy-5-fluorouridine and medroxyprogesterone acetate for recurrent breast cancer patient Gan to Kagaku Ryoho. Cancer and ChemoTherapy 22(6): 799-804
Takatsuka, Y.; Katoh, T.; Tsumura, I.; Kobayakawa, K.; Kawahara, T. 1992: Successful treatment of disseminated breast cancer with combination therapy of 5'-deoxy-5'-fluorouridine (5'-DFUR), medroxyprogesterone acetate (MPA) and cyclophosphamide (CPA) Gan to Kagaku Ryoho. Cancer and ChemoTherapy 19(1): 107-110
Mitsuyama, S.; Kuroda, Y.; Ohsato, K.; Nakamura, Y.; Murakami, F.; Nishikata, F.; Ikeda, S.; Egami, T.; Mori, A.; Ohe, H. 1996: Administration method and recurrence-preventing effect of medroxyprogesterone acetate (MPA) as a postoperative adjuvant endocrine therapy for stage III breast cancer. Kitakyushu Collaborative Study Group for Breast Cancer Gan to Kagaku Ryoho. Cancer and ChemoTherapy 23(9): 1153-1160
Kaunitz, A.M. 1996: Depot medroxyprogesterone acetate contraception and the risk of breast and gynecologic cancer Journal of Reproductive Medicine 41(5 Suppl): 419-427
Cohen, C.J.; Deppe, G.; Bruckner, H.W. 1977: Treatment of advanced adenocarcinoma of the endometrium with melphalan, 5-fluorouracil, and medroxyprogesterone acetate: a preliminary study Obstetrics and Gynecology 50(4): 415-417